title: Inhibition of diabetes in NOD mice by idiotypic induction of SLE.
abstract: The present study was undertaken to investigate whether active induction of systemic lupus erythematosus (SLE) in non-obese diabetic (NOD) mice could affect their development of insulin-dependent diabetes mellitus (IDDM). NOD mice were immunized with a human IgM mAb carrying the 16/6 idiotype (MIV-7) or with control human IgM. The mice were bled monthly and tested for SLE-associated autoantibodies in the serum and for the presence of leukopenia, thrombocytopenia, proteinuria and immunoglobulin deposits in the kidneys. The development of diabetes was determined by a blood glucose level exceeding 15 mM on two consecutive weekly determinations and by the presence of insulitis in the pancreas. The NOD mice immunized with MIV-7 developed high and persistent levels of autoantibodies, including anti-DNA, anti-histones and anti-cardiolipin, untreated mice and those immunized with normal human IgM did not produce these autoantibodies. The MIV-7-immunized mice also manifested an elevated erythrocyte sedimentation rate, leukopenia, thrombocytopenia and significant proteinuria, as well as deposits of Ig in their kidney glomeruli. Thus, NOD mice immunized with MIV-7 developed both autoantibodies and clinical features of SLE. The MIV-7-treated mice, however, showed a significantly lower incidence of IDDM (25%vs. 90%, P<0.003), accompanied by amelioration of the insulitis. The present study indicates that the induction of SLE by idiotypic immunization can protect NOD mice from developing IDDM, pointing to the importance of immune dysregulation in shift from one autoimmune disease to another.
authors.affiliation: Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: I
authors.initials: I
authors.lastname: Krause
authors.forename: Y
authors.initials: Y
authors.lastname: Tomer
authors.forename: D
authors.initials: D
authors.lastname: Elias
authors.forename: M
authors.initials: M
authors.lastname: Blank
authors.forename: B
authors.initials: B
authors.lastname: Gilburd
authors.forename: I R
authors.initials: IR
authors.lastname: Cohen
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D001323:Autoantibodies / Q000097:blood; D018834:Chaperonin 60 / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007114:Immunization; D007130:Immunoglobulin Idiotypes / Q000008:administration & dosage; D007075:Immunoglobulin M / Q000008:administration & dosage; D007668:Kidney / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000209:etiology* / Q000276:immunology; D051379:Mice; D016688:Mice, Inbred NOD
chemical_list: D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D018834:Chaperonin 60; D007130:Immunoglobulin Idiotypes; D007075:Immunoglobulin M